{"id":"https://genegraph.clinicalgenome.org/r/29767bfc-427d-43c0-a685-2927523ad739v1.0","type":"EvidenceStrengthAssertion","dc:description":"The relationship between the PNPLA2 gene and neutral lipid storage disease with myopathy (NLSDM), an autosomal recessive lysosomal storage disorder, was evaluated using the ClinGen Clinical Validity Framework as of July 9, 2022. PNPLA2 encodes patatin-like phospholipase domain-containing protein (aka adipose triglyceride lipase), an enzyme involved in triglyceride hydrolysis in adipocytes and in non-adipocyte droplets (PMID: 15550674) via catalyzing the hydrolysis of long-chain fatty acid esters at the sn2 position of the glycerol backbone. Among individuals with NLSDM, PNPLA2 deficiency leads to accumulation of incompletely degraded triglycerides in leukocytes and skeletal and cardiac muscle cells, resulting in the characteristic disease manifestations of myopathy and cardiomyopathy (PMID: 17187067, PMID: 21544567). \n\nThe disease mechanism of NLSDM is loss of function. NLSDM was first reported in 2007 (PMID: 17187067), and this publication was the first report of biallelic variants in PNPLA2 among patients with NLSDM. Both case-level (genetic) and experimental evidence support the relationship between PNPLA2 and NLSDM. Reported causal variants include missense, nonsense, frameshift, and splice-altering variants (PMID: 17187067, PMID: 21544567, PMID: 25956450, PMID: 24332944, PMID: 22832386). In total, 10 variants from eight probands in five publications were curated. Although there is additional published case-level evidence available, the maximum score for genetic evidence (12 points) has already been reached. \n\nExperimental evidence for the relationship between PNPLA2 and NLSDM includes the biochemical function of the gene product (patatin-like phospholipase domain-containing protein, aka adipose triglyceride lipase) being consistent with the clinical and biochemical findings identified individuals with NLSDM (PMID: 17187067, PMID: 21544567), the biochemical and clinical features of a PNPLA2 knockout mouse animal (PMID: 16675698), and rescue of a PNPLA2 knockout mouse model via reexpression of a wild-type PNPLA2 transgene (PMID: 21857651). Additional experimental evidence is available, but the maximum score for experimental evidence (6 points) has already been reached.\n\nIn sum, PNPLA2 is definitively associated with NLSDM. The association has been repeatedly demonstrated in both clinical and research settings, and has been upheld over time. This clinical validity classification was approved by the ClinGen Lysosomal Diseases GCEP on July 21, 2022 (SOP v9).","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/29767bfc-427d-43c0-a685-2927523ad739","GCISnapshot":"https://genegraph.clinicalgenome.org/r/fd21d68b-7688-4164-ba13-1ced669c4dfa","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/fd21d68b-7688-4164-ba13-1ced669c4dfa_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10110","date":"2022-09-29T14:19:46.995Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/fd21d68b-7688-4164-ba13-1ced669c4dfa_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10110","date":"2022-07-21T16:00:00.000Z","role":"Approver"}],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/fd21d68b-7688-4164-ba13-1ced669c4dfa_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/fd21d68b-7688-4164-ba13-1ced669c4dfa_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/fa33bbea-2fc0-4aff-bed6-5cc0d5d4c90c","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0e17619a-cd0b-487c-8b8f-75c579ec7f54","type":"Finding","dc:description":"Knockout mice show deficient PNPLA2 lipase enzymatic activity and accumulation of triglyceride droplets in multiple tissues, including muscle and heart cells, and die prematurely due to cardiomyopathy resulting from triglyceride accumulation in cardiac myocytes","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16675698","rdfs:label":"PNPLA2 knockout mouse","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/65e41ec3-ca78-4467-8c36-ed8e2d3843e3","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/badbe9c0-abe8-41b5-b7ab-a85f2b98dee6","type":"Finding","dc:description":"PMID: 21857651: in PNPLA2 knockout mice, reexpression of a PNPLA2 transgene in the hearts of the knockout mice hearts rescued the cardiac phenotype: in contrast to the triglyceride accumulation in the heart muscle tissue and premature death due to cardiomyopathy in knockout mice, mice with the PNPLA2 transgene showed normal levels of triglycerides and normal lifespan with normal cardiac function ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21857651","rdfs:label":"PNPLA2 knockout mouse rescue","demonstrates":{"id":"cg:PhenotypeRescue"}}],"specifiedBy":"GeneValidityNonHumanRescueCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":4},{"id":"https://genegraph.clinicalgenome.org/r/fd21d68b-7688-4164-ba13-1ced669c4dfa_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/89a7a3ab-9df0-42a9-a313-9ef6d9d37791","type":"EvidenceLine","dc:description":"Per ClinGen LD GCEP guidelines, gene products that have a well-established function in a metabolic pathway, supported by multiple studies over many years, and discussed in review papers are scored 2 points","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6aa47674-202c-4a5d-b112-80e1e79fe2db","type":"Finding","dc:description":"PNPLA2 encodes patatin-like phospholipase domain-containing protein (aka adipose triglyceride lipase), which is deficient among individuals with NLSDM (PMID: 17187067) \nPatatin-like phospholipase domain-containing protein is an enzyme involved in triglyceride hydrolysis in adipocytes and in non-adipocyte droplets (PMID: 15550674), via catalyzing the hydrolysis of long-chain fatty acid esters at the sn2 position of the glycerol backbone \nPNPLA2 deficiency leads to accumulation of incompletely degraded triglycerides in leukocytes and muscle cells (skeletal and cardiac myocytes), resulting in the characteristic disease manifestations of myopathy and cardiomyopathy (PMID: 17187067, PMID: 21544567)","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15550674","rdfs:label":"PNPLA2 encodes adipose triglyceride lipase","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":6},{"id":"https://genegraph.clinicalgenome.org/r/fd21d68b-7688-4164-ba13-1ced669c4dfa_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/334e5e07-9c38-4cc1-9ce0-6371ad6aef3a_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/23906e36-7b37-406c-a7d4-30cac3883d6c","type":"EvidenceLine","dc:description":"scored 1pt/variant to avoid double-counting for homozygous variant","calculatedScore":4,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/23906e36-7b37-406c-a7d4-30cac3883d6c_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"PMID: 24332944: shown via analysis of cDNA from patient fibroblasts to result in either exon 5 skipping (p.p.Arg163_Leu232del, including deleting Asp166 which is a critical catalytic residue) or  frameshift and premature truncation (p.Val233LeufsX162, which ‘lacks the hydrophobic carboxy terminus responsible for mediating lipid droplet binding’)","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/23906e36-7b37-406c-a7d4-30cac3883d6c_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24332944","allele":{"id":"https://genegraph.clinicalgenome.org/r/556f0b1e-b8d5-4966-9306-5839b56b688b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000011.10:g.822607G>C (GRCh38)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA378980662"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/334e5e07-9c38-4cc1-9ce0-6371ad6aef3a","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24332944","rdfs:label":"Case 2","allele":{"id":"https://genegraph.clinicalgenome.org/r/556f0b1e-b8d5-4966-9306-5839b56b688b"},"firstTestingMethod":"PCR","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/23906e36-7b37-406c-a7d4-30cac3883d6c_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/318816ca-5b36-40b1-a2c5-36d1d9fa8a7c_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2095174f-1db3-4f93-8c69-1696577df26e","type":"EvidenceLine","dc:description":"scored 0.75pts/variant to avoid double-counting for homozygous variant","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2095174f-1db3-4f93-8c69-1696577df26e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22832386","allele":{"id":"https://genegraph.clinicalgenome.org/r/d2e7e65b-9277-4dec-a711-e27fe4fb231c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_020376.4(PNPLA2):c.467del (p.Pro156fs)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA130659"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/318816ca-5b36-40b1-a2c5-36d1d9fa8a7c","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22832386","rdfs:label":"Patient 3","allele":{"id":"https://genegraph.clinicalgenome.org/r/d2e7e65b-9277-4dec-a711-e27fe4fb231c"},"detectionMethod":"PCR and Sanger sequencing of PNPLA2 gene","firstTestingMethod":"PCR","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/2095174f-1db3-4f93-8c69-1696577df26e_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/d90c37bb-33f7-4db4-86a9-de163c4ffc64_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/99dadfa3-6647-458c-be2d-729ea902c137","type":"EvidenceLine","dc:description":"scored 1pt/variant to avoid double-counting for homozygous variant","calculatedScore":4,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/99dadfa3-6647-458c-be2d-729ea902c137_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"PMID: 22832386: shown via RT-PCR analysis of skeletal muscle mRNA from patient to result in no detectable transcript","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/99dadfa3-6647-458c-be2d-729ea902c137_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22832386","allele":{"id":"https://genegraph.clinicalgenome.org/r/81f24083-9334-4018-b6b4-4b58a7f5178d","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_020376.4(PNPLA2):c.757+2T>C","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA130656"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/d90c37bb-33f7-4db4-86a9-de163c4ffc64","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22832386","rdfs:label":"Patient 2","allele":{"id":"https://genegraph.clinicalgenome.org/r/81f24083-9334-4018-b6b4-4b58a7f5178d"},"detectionMethod":"PCR and sanger sequencing of PNPLA2","firstTestingMethod":"PCR","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/99dadfa3-6647-458c-be2d-729ea902c137_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/29294038-e14f-4930-a1bb-4f79afa91609_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ce6b61ee-1c74-4db7-93c0-53ae692b5cb5","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ce6b61ee-1c74-4db7-93c0-53ae692b5cb5_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Functional data, PMID: 25956450: in transfected HeLa cells, showed significantly decreased lipase activity vs WT, as assessed by increased cellular lipid droplet content and triglyceride content","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/ce6b61ee-1c74-4db7-93c0-53ae692b5cb5_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25956450","allele":{"id":"https://genegraph.clinicalgenome.org/r/e8cc87c4-9d95-41d4-af29-8016710854cd","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_020376.4(PNPLA2):c.577A>T (p.Ile193Phe)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA378980242"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/f22daa40-8f0a-4399-b0b9-ccd4fd09d271","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f22daa40-8f0a-4399-b0b9-ccd4fd09d271_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Functional data, PMID: 25956450: in transfected HeLa cells, showed significantly decreased lipase activity vs WT, as assessed by increased cellular lipid droplet content and triglyceride content","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/f22daa40-8f0a-4399-b0b9-ccd4fd09d271_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25956450","allele":{"id":"https://genegraph.clinicalgenome.org/r/303d68b9-11e9-433e-9933-7cb083757410","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_020376.4(PNPLA2):c.167T>G (p.Leu56Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA378977213"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/29294038-e14f-4930-a1bb-4f79afa91609","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25956450","rdfs:label":"Family II:1","allele":[{"id":"https://genegraph.clinicalgenome.org/r/303d68b9-11e9-433e-9933-7cb083757410"},{"id":"https://genegraph.clinicalgenome.org/r/e8cc87c4-9d95-41d4-af29-8016710854cd"}],"detectionMethod":"PCR and sanger sequencing of PNPLA2 gene","firstTestingMethod":"PCR","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":[{"id":"https://genegraph.clinicalgenome.org/r/ce6b61ee-1c74-4db7-93c0-53ae692b5cb5_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/f22daa40-8f0a-4399-b0b9-ccd4fd09d271_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/fd21d68b-7688-4164-ba13-1ced669c4dfa_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5085425d-518f-4328-8312-c2720b912c3f_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25956450","rdfs:label":"Family II","estimatedLodScore":1.33,"family":{"id":"https://genegraph.clinicalgenome.org/r/5085425d-518f-4328-8312-c2720b912c3f","type":"Family","rdfs:label":"Family II","member":{"id":"https://genegraph.clinicalgenome.org/r/29294038-e14f-4930-a1bb-4f79afa91609"}},"meetsInclusionCriteria":true,"phenotypeNegativeAlleleNegative":1,"phenotypePositiveAllelePositive":3,"proband":{"id":"https://genegraph.clinicalgenome.org/r/29294038-e14f-4930-a1bb-4f79afa91609"},"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/6d7f561a-b93f-4b94-b477-d8d99e822209_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ba288432-e38b-4ebb-a69d-211811a7b9e1","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ba288432-e38b-4ebb-a69d-211811a7b9e1_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17187067","allele":{"id":"https://genegraph.clinicalgenome.org/r/ca62e97c-42a7-47b3-8f6a-bc5e93959bbc","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_020376.4(PNPLA2):c.584C>T (p.Pro195Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA115259"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/a612a3b8-3475-428d-bc7f-1050b6346fe0","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a612a3b8-3475-428d-bc7f-1050b6346fe0_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17187067","allele":{"id":"https://genegraph.clinicalgenome.org/r/1c6aec48-e920-4e9d-8330-fd113be6eb09","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_020376.4(PNPLA2):c.808del (p.His270fs)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA115258"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/6d7f561a-b93f-4b94-b477-d8d99e822209","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17187067","rdfs:label":"Individual 1","allele":[{"id":"https://genegraph.clinicalgenome.org/r/1c6aec48-e920-4e9d-8330-fd113be6eb09"},{"id":"https://genegraph.clinicalgenome.org/r/ca62e97c-42a7-47b3-8f6a-bc5e93959bbc"}],"detectionMethod":"PCR amplification and Sanger sequencing of PNPLA2 gene; ABHD5 gene was also sequenced (as alternate molecular cause)","firstTestingMethod":"PCR","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":[{"id":"https://genegraph.clinicalgenome.org/r/ba288432-e38b-4ebb-a69d-211811a7b9e1_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/a612a3b8-3475-428d-bc7f-1050b6346fe0_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.6},{"id":"https://genegraph.clinicalgenome.org/r/21efdeec-61a8-48b6-bd2c-f9320d673257_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/800030a5-cdcc-43b8-9834-f5c808661998","type":"EvidenceLine","dc:description":"scored 0.75pt/variant to avoid double-counting for homozygous variant","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/800030a5-cdcc-43b8-9834-f5c808661998_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21544567","allele":{"id":"https://genegraph.clinicalgenome.org/r/9693abc5-e0d6-4d3d-ac09-d4e55aa463a6","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_020376.4(PNPLA2):c.613dup (p.Leu205fs)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA144790"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/21efdeec-61a8-48b6-bd2c-f9320d673257","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21544567","rdfs:label":"Patient 1","allele":{"id":"https://genegraph.clinicalgenome.org/r/9693abc5-e0d6-4d3d-ac09-d4e55aa463a6"},"detectionMethod":"PCR and Sanger sequencing of PNPLA2 gene","firstTestingMethod":"PCR","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/800030a5-cdcc-43b8-9834-f5c808661998_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/8df0ec09-525e-4f8d-a1a6-4348f75e96dc_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/27814749-d03c-4078-bf3e-7cae5c9f9b98","type":"EvidenceLine","dc:description":"scored 1pt/variant to avoid double-counting for homozygous variant","calculatedScore":4,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/27814749-d03c-4078-bf3e-7cae5c9f9b98_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Functional data, PMID: 32542055: in Lunet N hCD81 cells, resulted in reduced lipase activity (as indexed by significantly higher cellular lipid droplet content) vs WT ","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/27814749-d03c-4078-bf3e-7cae5c9f9b98_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17187067","allele":{"id":"https://genegraph.clinicalgenome.org/r/666c5450-19cf-48be-9790-0b761749d3e3","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_020376.4(PNPLA2):c.865C>T (p.Gln289Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA115261"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/8df0ec09-525e-4f8d-a1a6-4348f75e96dc","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17187067","rdfs:label":"Individual 3","allele":{"id":"https://genegraph.clinicalgenome.org/r/666c5450-19cf-48be-9790-0b761749d3e3"},"detectionMethod":"PCR and Sanger sequencing of PNPLA2; ABHD5 gene also sequenced to rule out alternate genetic cause","firstTestingMethod":"PCR","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/27814749-d03c-4078-bf3e-7cae5c9f9b98_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/70046a21-2225-415a-909a-bce94bd08e7a_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ca49053b-050a-41a3-888f-1e75260b7b57","type":"EvidenceLine","dc:description":"scored 0.75pts/variant to avoid double-counting for homozygous variant","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ca49053b-050a-41a3-888f-1e75260b7b57_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21544567","allele":{"id":"https://genegraph.clinicalgenome.org/r/3f61cc7b-0989-4e5f-b711-9967cf225ab5","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_020376.4(PNPLA2):c.543del (p.Ile182fs)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA144791"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/70046a21-2225-415a-909a-bce94bd08e7a","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21544567","rdfs:label":"Patient 4","allele":{"id":"https://genegraph.clinicalgenome.org/r/3f61cc7b-0989-4e5f-b711-9967cf225ab5"},"detectionMethod":"PCR and sanger sequencing of PNPLA2 gene","firstTestingMethod":"PCR","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/ca49053b-050a-41a3-888f-1e75260b7b57_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.5}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12}],"evidenceStrength":"Definitive","sequence":5083,"specifiedBy":"GeneValidityCriteria9","strengthScore":18,"subject":{"id":"https://genegraph.clinicalgenome.org/r/8U5AJ4jaAnY","type":"GeneValidityProposition","disease":"obo:MONDO_0012545","gene":"hgnc:30802","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_fd21d68b-7688-4164-ba13-1ced669c4dfa-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}